A Phase 3 Study of HS-20094 in Patients With T2DM

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 546 participants.

Also called NCT07156539

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 546 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07156539
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07156539. Randomized; no masking; primary purpose treatment. Start 2025-09-30 (anticipated); primary completion 2027-03-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study of HS-20094 in Patients With T2DM
Intervention (Drug)
HS-20094 Injection
Intervention (Drug)
Dulaglutide Injection
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07156539
Content hash
63125461f974a7c0e443bce49dd2de65cd6a4e6af13945c00dad5e4bb8d1441d